Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Company signs contract for prototype module for DNA manufacturing
September 14th, 2005
CytoGenix, Inc., (CYGX) announced the signing of a contract with the engineering firm of Alfa Laval Biokinetics for the design and construction of a prototype production module for CytoGenix's high-throughput DNA manufacturing technology. The production module will be a self-contained, closed-loop system that will produce gram quantities of high-purity DNA in a single pass. Delivery is planned for fourth-quarter 2005. Traditionally, DNA for therapeutic compounds is made in fermentation vats using cloned E. coli bacteria. The bacteria are cultured and the DNA is extracted by rupturing the walls of the bacterial cells. This bioprocess produces...
Source: Vaccine Weekly (2005-09-14)
|
